共 50 条
- [41] Adjuvant nivolumab in high-risk stage IIb/IIc melanoma patients: Results from investigator initiated clinical trial.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Wilson, MelissaGeskin, Larisa J.Carvajal, Richard D.Mehnert, Janice M.Chiuzan, CodyLeiby, BenjaminSenter, KatherineSchuchter, Lynn MaraWeight, Ryan MichaelMastrangelo, Michael J.Berger, Adam C.
- [42] Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)BLOOD, 2017, 130Lane, Andrew A.Sweet, Kendra L.Wang, Eunice S.Donnellan, WilliamWalter, Roland B.Mantzaris, IoannisMaris, Michael B.Bixby, Dale L.Rizzieri, David A.Faderl, StefanMalinowski, MadlenPemmaraju, NaveenWysowskyj, HalynaShemesh, ShayChen, JaniceLindsay, RossBrooks, ChristopherGoswami, TrishnaStone, Richard M.Kantarjian, Hagop M.Jabbour, Elias J.Konopleva, Marina
- [43] Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)BLOOD, 2017, 130Popat, RakeshDe Tute, Ruth MaryCounsell, NicholasDe-Silva, DunnyaPhillips, BethCavenagh, James D.Adedayo, ToyinBraganza, NivetteRoddie, ClaireStreetly, MathewSchey, StephenKoh, MickeyCrowe, JosephineQuinn, Michael F.D'Sa, ShirleyVirchis, Andres E.Cook, GordonCrawley, Charles R.Pratt, GuyCook, MarkSmith, PaulClifton-Hadley, LauraRabin, NeilOwen, Roger G.Yong, Kwee
- [44] Do patients with initially resected metastatic GIST benefit from 'adjuvant' imatinib (IM) treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial.JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 520S - 520SBui, B. N.Le Cesne, A.Ray-Coquard, I.Duffaud, F.Rios, M.Adenis, A.Bonpas, E.Perol, D.Berthaud, P.Blay, J.
- [45] Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)ANNALS OF ONCOLOGY, 2017, 28Westeel, V.Barlesi, F.Foucher, P.Lafitte, J-J.Domas, J.Girard, P.Tredaniel, J.Wislez, M.Dumont, P.Quoix, E.Raffy, O.Braun, D.Derollez, M.Goupil, F.Hermann, J.Devin, E.Pichon, E.Gury, J-P.Morin, F.Souquet, P-J.
- [46] Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaitedTRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 200 - 203Denis, Marc G.Herbreteau, GuillaumePons-Tostivint, Elvire
- [47] Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trialBone Marrow Transplantation, 2024, 59 : 431 - 434Ruth M. de TuteGordon CookDavid A. CairnsJulia M. BrownJamie CavenaghA. John AshcroftJohn A. SnowdenKwee YongEleni TholouliMatthew JennerAnna HockadayMark T. DraysonTreen C. M. MorrisAndy C. RawstronRoger G. Owen
- [48] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Rodriguez-Otero, PaulaMoreau, PhilippeDimopoulos, Meletios AthanasiosBeksac, MeralPerrot, AuroreBroijl, AnnemiekGay, FrancescaMina, Robertovan de Donk, Niels W. C. J.Schjesvold, FredrikDelforge, MichelEinsele, HermannSpencer, AndrewLonergan, SarahVieyra, DiegoSitthi-Amorn, AnnaCarson, Robin L.Blade, JoanBoccadoro, MarioSonneveld, Pieter
- [49] Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trialBONE MARROW TRANSPLANTATION, 2024, 59 (03) : 431 - 434de Tute, Ruth M.Cook, GordonCairns, David A.Brown, Julia M.Cavenagh, JamieAshcroft, A. JohnSnowden, John A.Yong, KweeTholouli, EleniJenner, MatthewHockaday, AnnaDrayson, Mark T.Morris, Treen C. M.Rawstron, Andy C.Owen, Roger G.
- [50] Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 169 - 169Slater, SusannaBryant, AnnetteAresu, MariaBegum, RuwaidaChen, Hsiang-ChiPeckitt, ClareLazaro-Alcausi, RetchelCarter, PaulAnandappa, GayathriKhakoo, ShelizeBranagan, GrahamGeorge, NicolAbulafi, MutiDuff, SarahWest, NicholasBucheit, LeslieRich, Thereasa A.Chau, IanStarling, NaureenCunningham, David